PARP inhibitor may be effective against some TNBC lacking BRCA mutations

(American Association for Cancer Research) The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA damage-repair pathways.